DS-7011a ( DrugBank: - )

---

1 disease

告示番号	疾患名（ページ内リンク）	臨床試験数
49	全身性エリテマトーデス	2

49. 全身性エリテマトーデス

---

臨床試験数 : 993 /  薬物数 : 702 - (DrugBank : 184) / 標的遺伝子数 : 116 - 標的パスウェイ数 : 200

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT05638802 (ClinicalTrials.gov)	March 2023	28/11/2022	A Study of DS-7011a in Patients With Systemic Lupus Erythematosus and Cutaneous Lupus Erythematosus	A Phase 1b/2, Double-Blind, Placebo-Controlled, Randomized, Parallel-Arm Study to Explore the Safety, Pharmacokinetics, and Proof of Biological Activity of DS-7011a in Patients With Systemic Lupus Erythematosus and Active Cutaneous Lupus Erythematosus	Systemic Lupus Erythematosus;Cutaneous Lupus Erythematosus	Drug: DS-7011a;Drug: Placebo	Daiichi Sankyo, Inc.	NULL	Not yet recruiting	18 Years	N/A	All	24	Phase 1/Phase 2	NULL
2	NCT05203692 (ClinicalTrials.gov)	February 2, 2022	20/1/2022	A Study of a Single Ascending Dose Study of DS-7011a in Healthy Subjects	A Phase 1, Subjects- and Investigator-Blinded, Sponsor-Unblinded, Placebo-Controlled, Randomized, Sequential Cohort Study to Assess the Safety, Pharmacokinetics, and Pharmacodynamics of Single Ascending Intravenous and Subcutaneous Doses of DS-7011a in Healthy Subjects	Systemic Lupus Erythematosus	Drug: DS-7011a;Drug: Placebo	Daiichi Sankyo, Inc.	NULL	Active, not recruiting	18 Years	45 Years	All	80	Phase 1	United States